Poster-Disease-modifying Therapy
October 25, 2021
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
Background: The treatment landscape for multiple sclerosis (MS) continues to evolve and many disease-modifying therapies (DMTs) with...
Poster-Disease-modifying Therapy
October 25, 2021
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Disease Modifying Therapies Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Background: Women with multiple sclerosis (MS) who become pregnant and utilize maternity services may find their use of disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) often experience disease activity despite receiving a...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...
Poster-Disease-modifying Therapy
October 25, 2021
Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS
Background: Over the past two and a half decades, there has been an exponential increase in FDA approvals of treatments for relapsing forms...
Poster-Disease-modifying Therapy
October 25, 2021
Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS
Background: Alemtuzumab (ALE) and ocrelizumab (OCR) are widely recognized as among the highest efficacy multiple sclerosis (MS) disease...
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...